THE TREND
(Boursier.com) – The CAC40 once again crossed 6,900 points this morning, rebounding 0.80% to 6,930 points and thus regaining the ground lost yesterday when it gave up more than 2% at the start of the session … This sharp rebound remains subject to all the uncertainties surrounding Omicron’s impact on global growth as this variant continues to grow across the world.
For its part, the Nikkei recovered more than 2% this morning and the stock markets in China ended up, driven by real estate values. Beijing has urged large private and public real estate companies to buy real estate projects from struggling developers to reduce the risk of destabilizing the economy, the official China Securities Journal reported on Monday.
The start of the session in Paris was marked by the surge of Bolloré, which could sell its transport and logistics activities in Africa. An event in the history of the group. The title takes 10%.
WALL STREET
The US rating continued to correct on Monday, building on its momentum last weekend. There are still many uncertainties, particularly concerning the Omicron variant, shortages, inflation or the Biden plan, in a context of accelerated ‘tapering’ by the Fed … The Dow Jones fell by 1.23% to 34,032 pts, while the S&P 500 fell 1.14% to 4,568 pts. The Nasdaq lost 1.24% to 14.981 pts. A barrel of WTI crude falls back on the Nymex to $ 69.
ECO AND CURRENCIES
United States :
– Balance of current accounts. (2:30 p.m.)
Europe:
– German GfK consumer sentiment index. (08h00)
– European flash index of consumer confidence. (4:00 p.m.)
The euro / dollar parity reached $ 1.1279 this morning. A barrel of Brent is trading at $ 72.20. An ounce of gold is traded at $ 1,797.
RISING VALUES
Bollore (+ 10% to 4.77 Euros) announced that it had received an offer from the Swiss group MSC, specialist in sea freight, for its transport and logistics activities in Africa on the basis of an enterprise value of 5.7 Billions of Euro’s. Vincent Bolloré’s group has granted exclusivity to MSC until March 31, 2022 with a view to a possible promise to purchase. The Bolloré group has been present for more than half a century in Africa, where its subsidiary Bolloré Africa Logistics is the leader in transport and logistics. It employs nearly 21,000 people in 47 countries. Bolloré thus operates terminals, via concessions, in no less than 42 ports on the African continent, in particular in Côte d’Ivoire, Cameroon, Gabon and the Congo. It also has maritime agencies.
Casino (+ 1% to 22.91 Euros): GreenYellow, a subsidiary of the group and expert in decentralized solar photovoltaic production, will provide renewable electricity for Amazon’s activities. Amazon Web Services (AWS) will support the Casino group in its digital transformation.
TotalEnergies (+ 0.85% to 43.73 Euros) commissioned the largest battery energy storage site in France. Located within the Etablissement des Flandres in Dunkirk, this site meets the need for network stabilization, has a power of 61 MW, and a total storage capacity of 61 MWh. It is made up of 27 2.5 MWh containers designed and assembled by Saft, the battery subsidiary of TotalEnergies, which notably develops advanced batteries for industry.
Covivio (+ 1.45% to 69.58 Euros) announces the sale to Crédit Agricole Assurances, for a total amount of 325 ME, of its share in two office buildings: Carré Suffren, building of 25,000 m (2) located in the 15th arrondissement of Paris, and the Eiffage Campus, a 33,000 m (2) complex located in Vélizy-Villacoublay. With this transaction, Covivio will have signed new sales commitments for more than € 880 million since the start of the year, with an average margin of + 3.4% on the last appraised values. With this transaction, Covivio has signed new sales since the beginning of the year for 880 ME, thus exceeding its objective set at more than 600 ME for the year 2021. Achieved with an average margin of + 3.4% over the last appraised values, this success reflects the attractiveness of investors for quality office buildings.
FALLING VALUES
DBV (-25% at 3.66 Euros) believes that the realization of a new pivotal phase 3 clinical study controlled by placebo, similar to PEPITES (V712-301), constitutes the most direct and effective means for the progression and the advancement of the regulatory path of Viaskin Peanut. DBV also considers this approach to be the most straightforward to demonstrate the efficacy, safety and improvement of in vivo adhesion of the modified Viaskin Peanut system. The FDA confirmed that DBV’s change in strategy was acceptable in its oral and written discussions. DBV has started work on a protocol for the placebo-controlled Phase 3 efficacy study with mVP, and will seek agreement with the FDA before the initiation of the new trial. The Company is in the process of finalizing the new protocol for the pivotal Phase 3 study and intends to submit this protocol to the FDA by the end of February 2022.
THEY PUBLISHED THEIR TURNOVER / RESULTS …
–
THE LATEST “RECOS” FROM ANALYSTS …
UBS goes back from ‘neutral’ to ‘buy’ on Deutsche Börse, targeting a price of 165 euros.
MARKET INFO
Societe Generale completes the share buyback program for a total amount of 467.7 ME.
Carbios : the EIB grants a loan of 30 ME.
IN SHORT
Latécoère invests in breathing specialist Caeli Nova.
Safe Orthopedics : first clinical benefits at 3 months and worldwide launch of Sycamore.
Sanofi will acquire Amunix for its immuno-oncology portfolio.
SEB strengthens its presence in Africa.